Clinical use of cardiovascular risk score

Clinical Use of a Proteomic Cardiovascular Risk Score Positively Drives Patient Attitudes and Behavior Change

Introduction: The American Heart Association has outlined strategic impact goals designed to improve the cardiovascular health of Americans by 20% by the year 2020 including improvements in lifestyle and behavior.

Hypothesis: We assessed the hypothesis that sharing with patients a 7-protein cardiovascular risk score would motivate them to better adhere to cardiovascular risk reduction measures. 

Methods: The 7-protein risk score (SomaScan® CVD Secondary Risk Panel, SomaLogic) provides % risk by year for experiencing a cardiovascular event up to 5 years. Patients with stable coronary heart disease received a baseline lifestyle and behavior survey, chart abstraction, and blood draw for the 7-protein risk score. Results were shared with the patient by their physician. One month after receiving the panel results, patients were surveyed on the overall impact of the panel on health, lifestyle, and medication changes.

Results: Among the 198 enrolled patients, 25% had ≥ 20% predicted risk of a cardiovascular event in 5 years. Of the 131 patients with follow-up survey results to date, higher risk patients reported higher rates of desirable lifestyle changes, including healthier diet (Figure 4). Lower risk patients stated they would maintain their lifestyle to remain healthy.

Conclusions: Patients presented with their personal 7-protein cardiovascular risk score were motivated to improve their lifestyle and adherence to medications. The additional motivation from the test results, if sustained long-term, may translate into improved outcomes in patients with coronary heart disease.

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email